Duchenne Muscular Dystrophy Diagnosis and Management

Diagnostic Approach

• In male children, unexplained elevated transaminases are a classic presentation of Duchenne muscular dystrophy (DMD) because AST and ALT are produced by both liver and muscle cells 1, 2, 3, 4
• The American Academy of Pediatrics recommends that DMD should be considered in the differential diagnosis of any male child with elevated creatine kinase (CK) levels, particularly if the levels are very high (>10,000 U/L) and fluctuating 1, 2, 5
• Normal C-reactive protein (CRP) levels indicate the absence of an infectious or inflammatory process and support the diagnosis of a muscle disease 1

Diagnostic Testing

• Genetic testing for dystrophin gene deletions or duplications should be performed on a blood sample 1, 2, 5
• If genetic testing is negative, a muscle biopsy may be necessary to evaluate dystrophin protein expression 1, 2, 5
• The American College of Medical Genetics recommends that genetic counseling and testing be offered to all families with a history of DMD 1, 2, 5

Management

• Early diagnosis allows for timely initiation of glucocorticoid therapy, which can slow disease progression 1, 3
• A multidisciplinary care plan should be developed, including regular follow-up with a neurologist, physical therapist, and other specialists as needed 1, 2, 5
• Genetic counseling and testing should be offered to all families with a history of DMD, particularly female relatives who may be carriers 1, 2, 5

Prognosis

• Early diagnosis and treatment can improve outcomes for individuals with DMD, but the disease remains progressive and ultimately fatal 1, 3
• The American Academy of Pediatrics recommends that all individuals with DMD receive regular follow-up care and support to maximize quality of life and minimize complications 1, 2, 5

CK Levels in DMD Diagnosis

Characteristic Course of CK Levels

• The American Academy of Pediatrics notes that CK levels in DMD are typically very high, often exceeding 10,000 U/L, with the highest levels usually seen between 3-5 years of age 6

Alternative Diagnoses

• Acute rhabdomyolysis, caused by infection, trauma, medication, or metabolic disorders, can lead to rapid increases and decreases in CK levels, according to the American Academy of Pediatrics 6

Treatment and Management

• The European Academy of Neurology recommends that early diagnosis of DMD allows for timely initiation of glucocorticoid treatment, which can slow disease progression 7

Duchenne Muscular Dystrophy Diagnosis in Infants

Introduction to DMD Diagnosis

• The American Academy of Neurology recommends that Duchenne Muscular Dystrophy (DMD) be considered in infants with high CK levels, especially after physical activity, as it is a classic presentation of the disease 8, 9
• The presence of high CK levels (>10,000 U/L) in a 7-month-old infant is particularly significant and warrants immediate genetic testing for DMD 8, 9

Diagnostic Approach

• The European Academy of Neurology suggests that genetic testing for DMD should be performed as soon as possible in infants with high CK levels, as early diagnosis can lead to timely treatment and improved outcomes 8, 9
• A muscle biopsy may be necessary if genetic testing is negative, to evaluate dystrophin protein expression 8, 9
• The American College of Medical Genetics recommends that genetic counseling be offered to families with a history of DMD, especially female relatives who may be carriers 8, 9, 10

Importance of Early Diagnosis and Treatment

• Early diagnosis and treatment of DMD can slow disease progression and improve outcomes, highlighting the need for prompt genetic testing and medical evaluation 8, 9
• The use of glucocorticoids has been shown to improve outcomes in DMD patients, and early treatment can lead to better results 8, 9
• Multidisciplinary care, including physical therapy, occupational therapy, and respiratory support, is essential for managing DMD and improving quality of life 8, 9, 10

Post-Diagnosis Care

• After a diagnosis of DMD is made, regular follow-up with a multidisciplinary team, including neurologists, cardiologists, and respiratory specialists, is crucial for managing the disease and preventing complications 8, 9, 10
• Patient and family support, as well as communication with patient organizations, can provide valuable resources and improve outcomes 8, 9, 10

DMD Diagnosis and Management

Diagnostic Approach

• The absence of dystrophin protein in muscle biopsy is sufficient to confirm the diagnosis of dystrophinopathy, regardless of genetic test results, and patients should be managed as having DMD 11
• Standard genetic tests (deletion/duplication analysis) detect approximately 95% of DMD mutations, but 5% may be missed 11
• If standard tests are negative, further genetic testing, including dystrophin gene sequencing, should be performed to detect point mutations or small deletions/insertions 12
• Advanced molecular analysis, such as multiplex ligation-dependent probe amplification (MLPA) and single-condition amplification/internal hybridization, should be used to detect mutations 12

Genetic Counseling

• All female family members at risk should receive genetic counseling, and carrier testing should be offered to mothers and sisters 11, 12
• Family planning and prenatal diagnosis options should be discussed with families 12

Patient and Family Support

• Patients and families should be provided with continuous education and psychosocial support, and realistic information about the disease course and expectations 11

Diagnostic Criteria and Management of Duchenne Muscular Dystrophy

Clinical Presentation and Diagnosis

• The American Academy of Neurology recommends measuring troponin to evaluate myocardial involvement, and performing ECG and echocardiogram or cardiac MRI for patients with suspected Duchenne Muscular Dystrophy (DMD) 13
• The presence of elevated aldolase, particularly aldolase A, in combination with elevated CK, strongly supports the diagnosis of primary muscle disease, according to the Journal of Clinical Oncology 13
• Elevated aldolase has been identified as a serum biomarker in murine models of DMD and confirmed in patients with DMD, as reported in the Journal of Clinical Oncology 13
• The European Academy of Neurology suggests that a mild elevation of CSF protein helps to exclude Guillain-Barré syndrome, which typically presents with more pronounced albuminocytological dissociation, acute ascending weakness, and absent or diminished deep tendon reflexes 14

Differential Diagnosis

• The American College of Cardiology recommends considering alternative diagnoses, such as Becker Muscular Dystrophy, when CK levels are lower than expected for DMD, and presenting a milder clinical picture with slower progression 13
• Autoimmune myositis is less likely given that muscle weakness is more typical than pain, and inflammatory markers (ESR and CRP) would be elevated, with positive autoantibody tests for myositis, as reported in the Journal of Clinical Oncology 13

Diagnostic Evaluation

• The European Society of Human Genetics recommends proceeding directly to genetic testing for deletions or duplications of the dystrophin gene in a blood sample, which detects approximately 95% of DMD mutations 13
• If standard genetic testing is negative, complete sequencing of the dystrophin gene should be performed to detect point mutations or small deletions/insertions, as suggested by the European Society of Human Genetics 13

Creatine Kinase Elevation in Duchenne Muscular Dystrophy: Pathophysiology and Diagnostic Implications

Genetic Basis and Membrane Instability

• Mutations in the dystrophin gene cause severe reduction or complete absence of dystrophin protein in skeletal muscle cells, eliminating the protein that normally stabilizes the muscle fiber membrane. 15
• Dystrophin normally links the intracellular cytoskeleton to the extracellular matrix through the dystrophin‑associated protein complex, providing mechanical stability during contraction. 16
• Without functional dystrophin, muscle cell membranes become fragile and are susceptible to mechanical‑stress‑induced damage, leading to continuous leakage of intracellular creatine kinase (CK) into the bloodstream. 16

CK Isoform Profile in Dystrophin‑Related Cardiomyopathy

• Elevated serum CK muscle isoforms (CK‑MM) are a distinguishing biomarker of X‑linked dilated cardiomyopathy associated with dystrophin mutations, helping to differentiate this condition from other forms of cardiomyopathy. 15